Last reviewed · How we verify

RT+CETUXIMAB — Competitive Intelligence Brief

RT+CETUXIMAB (RT+CETUXIMAB) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: EGFR inhibitor (monoclonal antibody) + radiation therapy combination. Area: Oncology.

phase 3 EGFR inhibitor (monoclonal antibody) + radiation therapy combination EGFR (epidermal growth factor receptor) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

RT+CETUXIMAB (RT+CETUXIMAB) — Associazione Volontari Pazienti Oncologici. RT+CETUXIMAB combines radiation therapy with cetuximab, an EGFR-blocking monoclonal antibody, to inhibit tumor cell growth and enhance radiosensitivity.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
RT+CETUXIMAB TARGET RT+CETUXIMAB Associazione Volontari Pazienti Oncologici phase 3 EGFR inhibitor (monoclonal antibody) + radiation therapy combination EGFR (epidermal growth factor receptor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (EGFR inhibitor (monoclonal antibody) + radiation therapy combination class)

  1. Associazione Volontari Pazienti Oncologici · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). RT+CETUXIMAB — Competitive Intelligence Brief. https://druglandscape.com/ci/rt-cetuximab. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: